NCT05804162View on ClinicalTrials.gov

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

August 12, 2023

Study Completion Date

September 18, 2023

Conditions
Obesity
Interventions
DRUG

Cagrilintide

Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.

DRUG

Cagrilintide Placebo

Participants will receive cagrilintide placebo subcutaneously once weekly.

DRUG

Moxifloxacin

Partcipants will receive a single dose of moxifloxacin orally.

DRUG

Moxifloxacin Placebo

Partcipants will receive a single dose of moxifloxacin orally.

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05804162 - A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants | Biotech Hunter | Biotech Hunter